Azithromycin versus amoxicillin/clavulanate in the treatment of acute sinusitis. 1999

I Klapan, and J Culig, and K Oresković, and M Matrapazovski, and S Radosević
Ear, Nose, and Throat Department, Zagreb University School of Medicine, Croatia.

OBJECTIVE To compare the efficacy and tolerability of a 3-day course of azithromycin with a 10-day course of amoxicillin/clavulanic acid in the treatment of acute sinusitis in adults. METHODS One hundred adult patients with acute sinusitis were included in an open, randomized study. Clinical diagnosis of sinusitis was confirmed by nasal endoscopy, sinus radiography, and (when possible) by culture of sinus aspirate. Patients were randomized to receive azithromycin (500 mg once daily for 3 days) or amoxicillin/clavulanate (625 mg every 8 hours for 10 days). RESULTS A significantly faster resolution of signs and symptoms of sinusitis was observed in the azithromycin-treated patients. By the end of therapy (days 10-12), 95% of the patients in the azithromycin group and 74% in the amoxicillin/clavulanate group were cured. The remaining patients' conditions were improved. By the follow-up visit, cure was achieved in 98% of the azithromycin-treated patients, and 91% of the amoxicillin/clavulanate-treated patients. Treatment failure was observed in three patients from the amoxicillin/clavulanate group, and relapse occurred in one patient from each group. Bacteriologic eradication was achieved in 23 of 23 and 21 of 24 patients treated with azithromycin and amoxicillin/clavulanate, respectively. Both drugs were well tolerated. Two patients (4%) from the azithromycin group and five patients (10%) from the amoxicillin/clavulanate group reported mild gastrointestinal disturbances. CONCLUSIONS In adults with acute sinusitis, a 3-day course of azithromycin was as effective and well tolerated as a 10-day course of amoxicillin/clavulanic acid. A significantly simpler dosage regimen and faster clinical effect were the advantages of azithromycin.

UI MeSH Term Description Entries
D008297 Male Males
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D012852 Sinusitis Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES. Sinus Infections,Infection, Sinus,Infections, Sinus,Sinus Infection,Sinusitides
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

I Klapan, and J Culig, and K Oresković, and M Matrapazovski, and S Radosević
January 2010, American journal of otolaryngology,
I Klapan, and J Culig, and K Oresković, and M Matrapazovski, and S Radosević
November 2006, Bosnian journal of basic medical sciences,
I Klapan, and J Culig, and K Oresković, and M Matrapazovski, and S Radosević
January 2007, American journal of otolaryngology,
I Klapan, and J Culig, and K Oresković, and M Matrapazovski, and S Radosević
January 1997, Chemotherapy,
I Klapan, and J Culig, and K Oresković, and M Matrapazovski, and S Radosević
January 2024, JAMA,
I Klapan, and J Culig, and K Oresković, and M Matrapazovski, and S Radosević
June 2001, International journal of clinical practice,
I Klapan, and J Culig, and K Oresković, and M Matrapazovski, and S Radosević
January 2024, JAMA,
I Klapan, and J Culig, and K Oresković, and M Matrapazovski, and S Radosević
September 1991, The American journal of medicine,
I Klapan, and J Culig, and K Oresković, and M Matrapazovski, and S Radosević
December 2003, The Journal of family practice,
I Klapan, and J Culig, and K Oresković, and M Matrapazovski, and S Radosević
February 2004, The Journal of family practice,
Copied contents to your clipboard!